Boston Partners
CCXI

Boston Partners’s ChemoCentryx, Inc. CCXI Stock Holding History

Boston Partners’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-255,815
Closed -$1.54M – 777
2016
Q3 		$1.54M Hold
255,815
– – ﹤0.01% 676
2016
Q2 		$1.15M Buy
+255,815
New +$960K ﹤0.01% 679

Other funds holding CCXI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Boston Partners's CCXI Position: Q4 2016 in Review

Boston Partners sold out of ChemoCentryx, Inc. (CCXI) in Q4 2016, closing a stake of 255,815 shares — an estimated $1.54M sold.

Boston Partners first reported a position in CCXI in Q2 2016 and held it in 2 quarters. The position peaked at $1.54M in Q3 2016. 89 funds tracked by Wall St. Rank hold CCXI as of Q4 2016.

  • Boston Partners reported no remaining ChemoCentryx, Inc. position as of Q4 2016 after selling out during the quarter.
  • Boston Partners sold 255,815 ChemoCentryx, Inc. shares in Q4 2016, an estimated $1.54M.
  • Boston Partners first reported a position in ChemoCentryx, Inc. in Q2 2016 and held it in 2 quarters.
  • Boston Partners's ChemoCentryx, Inc. position peaked at $1.54M in Q3 2016.
  • 89 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2016.

Based on Boston Partners's 13F filing for Q4 2016, filed 6 Feb 2017.